Overview
According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85% this is believed to prevent close to three million deaths from diseases, such as diphtheria, tetanus, whooping cough and measles. However, it has been reported that 25% of vaccines are damaged due to cold chain malfunction (improper distribution and shipping). In some countries, about 80% of the drugs are estimated to lose their potency due to inadequate temperature control during their cold chain transportation. For some vaccines, even the slightest variations in temperature / storage conditions can adversely alter product integrity and / or viability. Over time, technological advancements in the methods of biologics development and manufacturing have prompted the developers to explore the potential of thermostable vaccines and thermostable biologics. Thermostable vaccines can be stored at room temperature for prolonged period of time, thereby eliminating the need for cold chain requirements in storage and transportation. This enables reduction in costs incurred during storage and transportation and, subsequently, the overall costs involved in mass immunization projects. In addition, it allows the suppliers to deliver the products in safe and convenient manner even to far-flung destinations.
At present, several biopharmaceutical companies and clinical research institutes are engaged in the development of thermostable vaccines and thermostable biologics, taking into consideration the rising global population, growing demand for vaccines and specific requirements of large-scale immunization initiatives. Moreover, significant efforts are being put into the development of technologies / devices, which enables transition of conventional vaccines to thermostable vaccines. The market has witnessed substantial partnership activity over the last few years. The activity in this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of capable developer companies. Driven by the substantial progress in research in this domain, encouraging clinical trial results, and ongoing technological advancement, the thermostable vaccines and thermostable biologics market is anticipated to grow at a commendable pace in the mid to long-term.
Scope of the Report
The "Thermostable Vaccines and Biologics Market: Distribution by Type of Molecule (Vaccines and Proteins), Target Indications (Covid-19, Diabetes, Enteric Hyperoxaluria, Norovirus Infection and Rotavirus Infection), Type of Therapy, Key Players, and Key Geographical Regions (North America, Europe and Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2035" report features an extensive study of the current market landscape and future opportunity for the players involved in the development of thermostable vaccines and biologics for the treatment of a variety of disease conditions. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.
Amongst other elements, the report includes:
- An overview of thermostable vaccines and biologics market, featuring a detailed analysis of pipeline molecules, based on several relevant parameters, such as type of molecule, type of formulation, type of manufacturing technology, trial phase (clinical, preclinical and discovery), route of administration, type of storage conditions, type of disease indication (Covid-19, diabetes and others), and target therapeutic area (infectious diseases, metabolic disorders, and others). It also includes information on the completed, ongoing and planned clinical trials for thermostable vaccines and biologics, sponsored by various industry players. It also provides insights on developer landscape along with the analysis based on several parameters, including year of establishment, company size, location of headquarters.
- An insightful competitiveness analysis of thermostable vaccines and biologics developers, taking into consideration the supplier strength (based on expertise of the manufacturer), product portfolio strength, portfolio diversity, and number of area(s) of application.
- A detailed analysis of close to 150 peer-review, scientific articles related to research on thermostable vaccines and biologics, such as year of publication, type of publication focus area (therapeutic area), impact factor, most popular author and most popular journals.
- An analysis of the partnerships that have been inked by various stakeholders engaged in the development of thermostable vaccines and biologics, during the period 2015-2021, covering product development agreements, research and development agreements, licensing agreements, clinical trial agreement, licensing and manufacturing agreement, product development and commercialization manufacturing agreements, joint venture, product development and commercialization, acquisition and other types of partnership deals.
- An analysis of the investments made at various stages of development of the companies engaged in this field, covering instances of debt financing, equity investments, Secondary offerings, seed funding, award/grant funding, post-IPO Debt, post-IPO Equity, private equity and other types of funding deals.
- Tabulated profiles of the key players providing thermostable vaccines and biologics. Each profile includes an overview of the company, thermostable product portfolio, recent developments, and an informed future outlook.
One of the key objectives of the report was to estimate the future growth potential of thermostable vaccines and biologics market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the period 2021-2035. For this purpose, we have segmented the future opportunity across the following market segments: Type of Molecule (Vaccines and Proteins), Target Indications (Covid-19, Diabetes, Enteric Hyperoxaluria, Norovirus Infection and Rotavirus Infection), Type of Therapy, Key Players, and Key Geographical Regions (North America, Europe and Asia Pacific and Rest of the World). To account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry’s growth.
Key Questions Answered
- Who are the leading players engaged in the development of thermostable vaccines and biologics?
- Which are the key clinical conditions that can be treated by thermostable vaccines and biologics?
- What is the trend of investment in this industry?
- Which partnership models are commonly adopted by stakeholders engaged in the development of thermostable vaccines and biologics domain?
- Which factors are likely to influence the evolution of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Table of Contents
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered Research Methodology
1.4. Chapter Outlines
2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. Overview of Vaccines and Biologics
3.3. Classification of Vaccines Based on Type of Active Ingredient
3.4. Limitations of Conventional Vaccines
3.5. Thermostable Vaccines and Biologics
3.5.1. Thermostability of Marketed Vaccines
3.5.2. Common Routes of Administration for Thermostable Vaccines
3.5.2.1. Oral Route
3.5.2.2. Intranasal Route
3.5.2.3. Intradermal Route
3.5.2.4. Inhalation Route
3.5.2.5. Intramuscular Route
3.6. Value Propositions of Thermostable Vaccines
3.7. Future Perspectives
4. Market Landscape: Thermostable Vaccines and Biologics
4.1. Chapter Overview
4.2. Thermostable Vaccines and Biologics: Product Pipeline
4.2.1. Analysis by Type of Biologics
4.2.2. Analysis by Type of Formulation
4.2.3. Analysis by Type of Manufacturing Technologies
4.2.4. Analysis by Trial Phase
4.2.5. Analysis by Route of Administration
4.2.6. Analysis by Type of Storage Condition
4.2.7. Analysis by Disease Indication
4.2.8. Analysis by Therapeutic Area
4.3. Thermostable Vaccines and Biologics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Developers: Analysis by Number of Products
5. Thermostable Vaccines and Biologics Manufacturers in North America
5.1. Chapter Overview
5.2. Allena Pharmaceuticals
5.2.1. Company Overview
5.2.2. Allena Pharmaceutical: Thermostable Product Portfolio
5.2.3. Recent Developments and Future Outlook
5.3. Amarillo Biosciences
5.3.1. Company Overview
5.3.2. Amarillo Biosciences: Thermostable Product Portfolio
5.4. Vaxart
5.4.1. Company Overview
5.4.3. Vaxart: Thermostable Product Portfolio
5.4.4. Recent Developments and Future Outlook
6. Thermostable Vaccines and Biologics Manufacturers in Europe
6.1. Chapter Overview
6.2. Tiziana Life Sciences
6.2.1. Company Overview
6.2.2. Tiziana Life Sciences: Thermostable Product Portfolio
6.3. Diabetology (A Subsidiary of Proxima Concepts)
6.3.1. Company Overview
6.3.2. Diabetology (A Subsidiary of Proxima Concepts): Thermostable Product Portfolio
7. Thermostable Vaccines and Biologics Manufacturers in Asia-Pacific
7.1 Chapter Overview
7.2. Biocon
7.2.1. Company Overview
7.2.2. Biocon: Product Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Serum Institute of India
7.3.1. Company Overview
7.3.2. Serum Institute of India: Product Portfolio
7.3.3. Recent Developments and Future Outlook
8. Company Competitiveness Analysis
8.1. Chapter Overview
8.2. Methodology
8.3. Assumptions/Key Parameters
8.4. Competitiveness Analysis: Thermostable Vaccines Service Providers
8.4.1. Competitiveness Analysis: Companies Offering Thermostable Vaccines in North America
8.4.2. Competitiveness Analysis: Companies Offering Thermostable Vaccines in Europe
8.4.3. Competitiveness Analysis: Companies Offering Thermostable Vaccines in Asia-Pacific
9. Publication Analysis
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Thermostable Vaccines and Biologics: Publication Analysis
9.3.1. Analysis by Publication Year
9.3.2. Analysis by Type of Publication
9.3.3. Analysis by Focus Area (Therapeutic Area)
9.3.4. Analysis by Impact Factor
9.3.5. Most Popular Authors: Analysis by Number of Publications
9.3.6. Most Popular Journals: Analysis by Number of Publications
10. Partnerships and Collaborations
10.1. Chapter Overview
10.2. Partnership Models
10.3. Thermostable Vaccines and Biologics: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type and Year of Partnership
10.3.4. Analysis by Type of Partner
10.3.5. Analysis by Year of Partnership and Type of Partner
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Geographical Analysis
10.3.7.1. Analysis by Intracontinental and Intercontinental Agreement
11. Funding and Investment Analysis
11.1. Chapter Overview
11.2. Types of Funding Instances
11.3. Thermostable Vaccines and Biologics: Recent Funding Instances
11.3.1. Analysis by Year of Investment
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Most Active Players: Analysis by Number of Funding Instances
11.3.5 Most Active Investors: Analysis by Number of Funding Instances
11.4. Concluding Remarks
12. Market Sizing and Opportunity Analysis
12.1. Chapter Overview
12.2. Scope and Limitations
12.3. Key Assumptions and Forecast Methodology
12.4. Overall Thermostable Vaccines and Biologics Market, 2021-2035
12.5. Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Type of Molecule
12.6. Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Type of Indication
12.7. Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Therapeutic Area
12.8. Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Key Players
12.8. Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Geographical Region
12.9. Product-Wise Sales Forecast
12.9.1. Rotasiil (Serum Institute of India)
12.9.1.1. Target Patient Population
12.9.1.2. Sales Forecast (Usd Million)
12.9.2. Vxa-A1.1(Vaxart)
12.9.2.1. Target Patient Population
12.9.2.2. Sales Forecast (Usd Million)
12.9.3. Vxa-Nvv-105 (Vaxart)
12.9.3.1. Target Patient Population
12.9.3.2. Sales Forecast (Usd Million)
12.9.4. Relaxoliase (Allena Pharmaceuticals)
12.9.4.1. Target Patient Population
12.9.4.2. Sales Forecast (Usd Million)
13. Conclusion
13.1. Chapter Overview
14. Executive Insights
15. Appendix 1: Tabulated Data
16. Appendix 2: List of Companies and Organizations
List of Figures
Figure 2.1 Executive Summary: Current Market Landscape of Thermostable Vaccines and Biologics
Figure 2.2 Executive Summary: Publication Analysis
Figure 2.3 Executive Summary: Partnership and Collaboration Analysis
Figure 2.4 Executive Summary: Funding Analysis
Figure 2.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Classification of Conventional Vaccines
Figure 4.1 Thermostable Vaccines and Biologics: Distribution by Type of Molecule
Figure 4.2 Thermostable Vaccines and Biologics: Distribution by Storage Conditions
Figure 4.3 Thermostable Vaccines and Biologics: Distribution by Type of Manufacturing Technologies
Figure 4.4 Thermostable Vaccines and Biologics: Distribution by Trial Phase
Figure 4.5 Thermostable Vaccines and Biologics: Distribution by Route of Administration
Figure 4.6 Thermostable Vaccines and Biologics: Distribution by Type of Indication
Figure 4.7 Thermostable Vaccines and Biologics: Distribution by Type of Therapeutic Area
Figure 4.8 Thermostable Vaccines and Biologics Developers: Distribution by Year of Establishment
Figure 4.9 Thermostable Vaccines and Biologics Developers: Distribution by Company Size
Figure 4.10 Thermostable Vaccines and Biologics Developers: Distribution by Location of Headquarters
Figure 4.11 Leading Developers: Distribution by Number of Products
Figure 8.1 Thermostable Vaccines and Biologics: Distribution by Company Competitiveness
Figure 8.2 Thermostable Vaccines and Biologics: Distribution in North America
Figure 8.3 Thermostable Vaccines and Biologics: Distribution in Europe
Figure 8.4 Thermostable Vaccines and Biologics: Distribution in Asia-Pacific
Figure 9.1 Thermostable Vaccines and Biologics: Distribution by Year of Publication Thermostable Vaccines and Biologics
Figure 9.2 Thermostable Vaccines and Biologics: Distribution by Most Popular Author
Figure 9.3 Thermostable Vaccines and Biologics: Distribution by Distribution by Impact Factor
Figure 9.4 Thermostable Vaccines and Biologics: Distribution by Most Popular Journal
Figure 9.5 Thermostable Vaccines and Biologics: Distribution by Therapeutic Area
Figure 10.1 Thermostable Vaccines and Biologics: Distribution by Year of Partnership
Figure 10.2 Thermostable Vaccines and Biologics: Distribution by Type of Partnership
Figure 10.3 Thermostable Vaccines and Biologics: Distribution by Year and Type of Partnership
Figure 10.4 Thermostable Vaccines and Biologics: Distribution by Type of Partner
Figure 10.5 Thermostable Vaccines and Biologics: Distribution by Location of Headquarters
Figures 10.6 Thermostable Vaccines and Biologics: Distribution by Intracontinental and Intercontinental Agreements
Figure 10.7 Leading Developers: Distribution by Number of Partnership
Figures 10.8 Thermostable Vaccines and Biologics: World Map Presentation Based on Number of Partnership
Figure 11.1 Thermostable Vaccine and Biologics: Distribution by Year of Investment
Figure 11.2 Thermostable Vaccine and Biologics: Distribution by Amount Invested
Figure 11.3 Thermostable Vaccine and Biologics: Distribution by Type of Funding
Figure 11.4 Leading Developers: Based on Number of Funding Instances
Figure 12.1 Figure 10.1 Global Thermostable Vaccines and Biologics Market, 2021-2035 (Usd Million)
Figure 12.2 Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Type of Therapy (Usd Million)
Figure 12.3 Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Therapeutic Approach (Usd Million)
Figure 12.4 Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Therapeutic Area (Usd Million)
Figure 12.5 Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Geographical Region (Usd Million)
Figure 12.6 Rotasiil Target Patient Population (Till 2035)
Figure 12.7 Rotasiil Sales Forecast (Till 2035): Base Scenario (Usd Million)
Figure 12.8 Vxa-A1.1 Target Patient Population (Till 2035)
Figure 12.9 Vxa-A1.1 Sales Forecast (Till 2035): Base Scenario (Usd Million)
Figure 12.10 Vxa-Nvv-105 Target Patient Population (Till 2035)
Figure 12.11 Vxa-Nvv-105 Sales Forecast (Till 2035): Base Scenario (Usd Million)
Figure 12.12 Relaxoliase Target Patient Population (Till 2035)
Figure 12.13 Relaxoliase Sales Forecast (Till 2035): Base Scenario (Usd Million)
Figure 13.1 Concluding Remarks: Current Market Landscape
Figure 13.2 Concluding Remarks: Company Competitiveness Analysis
Figure 13.3 Concluding Remarks: Publication Analysis
Figure 13.4 Concluding Remarks: Recent Partnerships
Figure 13.5 Concluding Remarks: Funding Analysis
Figure 13.6 Concluding Remarks: Market Sizing and Opportunity Analysis
List of Tables
Table 3.1 Thermostable Vaccines and Biologics: Classification Based on Method of Development.
Table 3.2 Thermostable Vaccines and Biologics: List of Conventional Vaccines Stable at Room Temperature
Table 4.1 Thermostable Vaccines and Biologics: Information on Type of Molecule, Route of Administration, Type of Formulation, Technology, Phase of Development, Storage Condition, Indication and Therapeutic Area.
Table 4.2 Thermostable Vaccines and Biologics Developers: Information of Year of Establishment, Company Size and Location of Headquarters
Table 4.3 Thermostable Vaccines and Biologics: List of Technologies and Developers
Table 5.1 Thermostable Vaccines and Biologics: List of Manufacturers in North America
Table 5.2 Allena Pharmaceuticals: Company Snapshot
Table 5.3 Allena Pharmaceuticals: Product Portfolio
Table 5.4 Allena Pharmaceuticals: Recent Developments and Future Outlook
Table 5.5 Amarillo Biosciences: Company Snapshot
Table 5.6 Amarillo Biosciences: Product Portfolio
Table 5.7 Vaxart: Company Snapshot
Table 5.8 Vaxart: Product Portfolio (Vxa-A1.1)
Table 5.9 Vaxart: Product Portfolio (Vxa.G1.1-Nn)
Table 5.10 Vaxart: Recent Developments and Future Outlook
Table 6.1 Thermostable Vaccines and Biologics: List of Manufacturers in Europe
Table 6.2 Diabeteology: Company Snapshot
Table 6.3 Diabeteology: Product Portfolio (Capsulin™ Ir)
Table 6.4 Diabeteology: Product Portfolio (Capsulin™ Oad)
Table 6.5 Tiziana Life Sciences: Company Snapshot
Table 6.6 Tiziana Life Sciences: Product Portfolio
Table 7.1 Thermostable Vaccines and Biologics: List of Manufacturers in Asia-Pacific
Table 7.2 Biocon: Company Snapshot
Table 7.3 Biocon: Product Portfolio
Table 7.4 Biocon: Recent Developments and Future Outlook
Table 7.5 Serum Institute of India: Company Snapshot
Table 7.6 Serum Institute of India: Product Portfolio
Table 7.7 Serum Institute of India: Recent Developments and Future Outlook
Table 8.1 Thermostable Vaccines and Biologics: Information on Title of Publication, Type of Study, Year of Publication, Focus Area, Target Therapeutic Area, Type of Journal and Pubmed Id
Table 10.1 Thermostable Vaccines and Biologics: List of Partnerships and Collaborations, 2015-2021(Till September)
Table 11.1 Thermostable Vaccines and Biologics: List of Funding Instances. 2015-2021 (Till September)
Table 12.1 Thermostable Vaccines and Biologics: Expected Launch Years of Advanced Stage Candidates
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acorn Biomedical
- Aegis Therapies
- Affilogic
- Allena Pharmaceuticals
- Altimmune
- Amarillo Biosciences
- Aphios
- Arecor
- Assembly Biosciences
- Avaxia Biologics
- Batavia Biosciences
- Biocon
- BioLingus
- Chiasma Pharma
- Cosmo Pharmaceuticals
- Creative Biolabs
- CureVac
- Diabetology
- Diasome Pharmaceuticals
- Elarex
- Enesi Pharma
- enGene
- Entera Bio
- Entrega
- Enteris BioPharma
- Esperovax
- Evonik
- Gattefosse
- Generex Biotechnology
- Iconovo
- ImmunityBio
- Immuron
- Innovate UK
- Intrexon
- Inventprise
- iosBio
- Jordanian Pharmaceutical Manufacturing
- Jurata Thin Film
- Latch Medical
- Longevity Biotech
- Micron Biomedical (Micron)
- MidaSol Therapeutics
- Midatech Pharma
- MigVax
- Mynvax
- NanoMega Medical
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Niagara University
- Nova Laboratories
- Nutrinia
- Oramed Pharmaceuticals
- Oravax Medical
- Prokarium
- Protagonist Therapeutics
- Proxima Concepts
- PvP Biologics
- QuadMedicine
- Rani Therapeutics
- Rapid Dose Therapeutics (RDT)
- Serum Institute of India
- Sigmoid Pharma
- Soligenix
- StoneStable
- Swansea University
- Synergy Pharmaceuticals
- Tamarix Technologies Group
- TFF Pharmaceuticals
- Tiziana Life Sciences
- Transgene Biotek
- Universal Stabilization Technologies (UST)
- University of Montreal
- Vaxart
- Vaxess Technologies
- Vaxxas
- VBI Vaccines
- Verndari
- VHsquared
- ViroVet Livestock Solutions
- VitriVax
- XBiotech
- Ziccum
Methodology
LOADING...
